Hemostemix Inc. (CVE:HEM – Get Free Report) rose 29.4% during trading on Friday . The stock traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares traded hands during trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The stock’s 50 day simple moving average is C$0.09 and its 200-day simple moving average is C$0.10. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a market cap of C$20.73 million, a price-to-earnings ratio of -4.07 and a beta of 1.25.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- NEW LAW: Congress Approves Setup For Digital Dollar?
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Is a 93% win rate actually possible?
- Why Trump and Musk suddenly care about Fort Knox
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
